Rocket Pharmaceuticals (STU:9IP1) Cyclically Adjusted Book per Share: €6.28 (As of Mar. 2026)


STU:9IP1 Rocket Pharmaceuticals Inc STU:9IP1
31 GF Score
Price €3.29
! 3 Warning Signs
View Full Analysis

What is Rocket Pharmaceuticals Cyclically Adjusted Book per Share?

Rocket Pharmaceuticals STU:9IP1 -1.79% 31 Cyclically Adjusted Book per Share is €6.28 as of Mar. 2026. GuruFocus rates STU:9IP1 with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Rocket Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €1.887. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €6.28 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Rocket Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -13.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-06), Rocket Pharmaceuticals's current stock price is €3.29. Rocket Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €6.28. Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.52.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Rocket Pharmaceuticals was 0.53. The lowest was 0.00. And the median was 0.00.


Rocket Pharmaceuticals  (STU:9IP1) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.29/6.28
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Rocket Pharmaceuticals was 0.53. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Rocket Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Rocket Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Rocket Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rocket Pharmaceuticals Cyclically Adjusted Book per Share Chart

Rocket Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 7.39 7.74 6.31

Rocket Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.01 7.30 6.88 6.31 6.28

STU:9IP1 vs TENX, DMAC, AVIR: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rocket Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


STU:9IP1
31GF Score
Rocket Pharmaceuticals Inc STU:9IP1
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rocket Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rocket Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.887/330.2130*330.2130
=1.887

Current CPI (Mar. 2026) = 330.2130.

Rocket Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 12.616 241.018 17.285
201609 11.255 241.428 15.394
201612 10.281 241.432 14.062
201703 8.767 243.801 11.874
201706 7.582 244.955 10.221
201709 6.296 246.819 8.423
201712 5.930 246.524 7.943
201803 3.502 249.554 4.634
201806 3.403 251.989 4.459
201809 3.090 252.439 4.042
201812 3.774 251.233 4.960
201903 3.474 254.202 4.513
201906 4.370 256.143 5.634
201909 4.182 256.759 5.378
201912 5.050 256.974 6.489
202003 4.696 258.115 6.008
202006 4.290 257.797 5.495
202009 3.720 260.280 4.720
202012 6.786 260.474 8.603
202103 6.504 264.877 8.108
202106 6.403 271.696 7.782
202109 6.406 274.310 7.712
202112 6.239 278.802 7.389
202203 5.877 287.504 6.750
202206 5.571 296.311 6.208
202209 5.469 296.808 6.085
202212 5.842 296.797 6.500
202303 5.330 301.836 5.831
202306 4.619 305.109 4.999
202309 5.624 307.789 6.034
202312 5.003 306.746 5.386
202403 4.481 312.332 4.738
202406 3.929 314.175 4.130
202409 3.261 315.301 3.415
202412 4.156 315.605 4.348
202503 3.571 319.799 3.687
202506 2.847 322.561 2.915
202509 2.470 324.800 2.511
202512 2.186 324.054 2.228
202603 1.887 330.213 1.887

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €6.28 mean?
Rocket Pharmaceuticals (STU:9IP1) has a Cyclically Adjusted Book per Share of €6.28 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Rocket Pharmaceuticals and its competitors.
Is Rocket Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Rocket Pharmaceuticals' current Cyclically Adjusted Book per Share is €6.28. Overall, Rocket Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Pharmaceuticals' Cyclically Adjusted Book per Share compare to TENX and DMAC?
Rocket Pharmaceuticals' Cyclically Adjusted Book per Share of €6.28 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Rocket Pharmaceuticals and its competitors. Rocket Pharmaceuticals's current Cyclically Adjusted Book per Share is €6.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Pharmaceuticals stock overvalued right now?
Rocket Pharmaceuticals (STU:9IP1) has a current Cyclically Adjusted Book per Share of €6.28. The current Cyclically Adjusted Book per Share is €6.28. Rocket Pharmaceuticals' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Rocket Pharmaceuticals (STU:9IP1), the current Cyclically Adjusted Book per Share is €6.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rocket Pharmaceuticals Business Description

Other Exchanges RCKT:USA
Address 9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
31GF Score

Get the complete analysis for STU:9IP1

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.29
Price